ISSN: 1859 - 2872
Relationship between the results of stereotactic body radiation therapy with some clinical and paraclinical characteristics in patients with peripheral early stage non-small cell lung cancer
Main Article Content
Keywords
Abstract
Summary
Objective: To evaluate the relationship between the result of stereotactic body radiation therapy (SBRT) with some clinical and paraclinical in peripheral early stage non-small cell lung cancer (NSCLC) patients (T1-2aN0M0). Subject and method: Prospective, follow-up 23 NSCLC patients stage I (T1-2aN0M0) with peripheral tumor, who were received SBRT, follow-up and evaluated from January, 2015 to December, 2020. The endpoints were the relationship between some clinical and paraclinical to the response rate, progression free surviva (PFS) and overall survival (OS). Result: The average age was 65.1 years-old, the mean of diameter was 3.31cm. The median of follow-up was 26 months, objective response rate was 91.3%, disease control rate was 95.7%. The median PFS was 26 months, median OS was 58 months. Mean of SUVmax was 7.77 decrease to 4.99 after SBRT, the difference was statistically significant with p=0.000, the change of CEA and Cyfra 21-1 was no statistically significant (p>0.05). The median PFS and OS higher in patients with no smoking, no weight loss, performance status (PS) 0 - 1 and patients with tumor ≤ 3cm compare patients with smoking, weight loss, PS 2 and patients with tumor > 3cm (p>0.05). There was no statistically significant in median PFS and OS between patients refused surgery and those who have medical inoperable. There was no correlation between time of smoking, pack-year, the dose of SBRT, CEA, Cyfra 21-1 and SUVmax before and after to survival time of patients. Conclusion: SBRT was a good option of treatment for patients with early stage NSCLC. SUVmax relate to response of SBRT but it was not prognostic factor to survival time. There were not characteristics relate to survival time of patients after SBRT.
Keywords: Early stage non-small cell lung cancer, stereotactic body radiation therapy.
Article Details
References
2. Jessica D, Mark F, Peter M et al (2012) American College of Chest Physicians and Society of Thoracic Surgeons Consensus Statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. Chest 142(6): 1620-1635.
3. Bryan JS, Megan ED, Erin BK et al (2017) Stereotactic Body Radiation Therapy for Early-stage non-small cell lung cancer: American Society for Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol 36: 710-719.
4. Ashwin S, Richard L, Jae K et al (2018) Stereotactic Body Radiation Therapy (SBRT) for early stage lung cancer in the elderly. Seminars in Oncology 45: 210-219.
5. Achilles JF, Ronald CMcG, Constaitin TY et al (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: Four-year results of a prospective phase ii study. Int J Radiat Oncol Biol Phys 75(3): 677-682.
6. Hiroshi O, Tsutomu A, Hiroki S et al (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101(7): 1623-1631.
7. Robert T, Rebecca P, Jame G et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11): 1070-1076.
8. Nagata Y, Hiraoka M, Shibata T et al (2012) Stereotactic body radiation therapy For T1N0M0 Non-small cell lung cancer first report for Inoperable population of a phase II trial by Japan Clinical Oncology Group (JCOG 0403), Int J Radiat Oncol Biol Phys 84(Suppl): 46-46.
9. Umberto R, Andrea Riccardo F, Alessia G et al (2010) Stereotactic body radiation therapy for early stage non-small cell lung cancer: Results of a prospective trial. Lung Cancer 68(1): 72-77.
10. Pia B, Jan N, Morten H et al (2009) Outcome in a prospective phage II trial of medically Inoperable stage I non-small cell lung cancer patients treated with Stereotactic Body Radiation Therapy. J Clin Oncol 27: 3290-3296.
11. Atsuya T, Naoko S, Hirofumi F et al (2014) Maximim standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small cell lung cancer patients after stereotactic body radiationtherapy. J Thorac Oncol 9: 65-73.
12. Yuta S, Chisa H, Fumiya B et al (2012) Stereotactic body radiation therapy using a radiobiology-based regimen for stage i non-small cell lung cancer, a muticenter study. Cancer 15: 2078-2084.
13. Caitlin AS, Marian H, Abigail D et al (2018) Five-year long term outcomes of Stereotactic Body Radiation Therapy for operable versus medically inoperable stage I non-small cell lung cancer: analysis by operability, fractionation regimen, tumor size and tumor location. Clinical Lung Cancer 20(1): 63-71.
14. Qingren L, Xiaojiang S, Ning Z et al (2019) Outcomes of stereotactic body radiotherapy versus lobectomy for stage I non-small cell lung cancer: a propensity score matching analysis. BMC Pulmonary Medicine 19: 98.
15. Joe YC, Suresh S, Marinus AP et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: A pooled analysis of two randomised trials. Lancet Oncology 16(6): 630-637.
Article Sidebar
